Benzene Ring Nonionically Bonded Patents (Class 514/567)
-
Publication number: 20140378546Abstract: The present disclosure relates to a more effective therapeutic agent capable of improving and treating the axial symptoms (particularly freezing of gait symptom) of patients with Parkinson's disease. Such symptoms in patients with Parkinson's disease can be improved and treated by using L-threo-3,4-dihydroxy-phenylserine (DOPS) and a COMT inhibitor in combination together, optionally with an L-DOPA preparation as well. As a result, the axial symptoms difficult to improve with conventional L-DOPA preparations can be treated, and a therapeutic agent and a treatment method are provided for the axial symptoms of patients with Parkinson's disease, particularly those suffering from the disease at a moderate level or higher.Type: ApplicationFiled: May 14, 2012Publication date: December 25, 2014Applicant: Chelsea Therapeutics, IncInventors: Saburo Sakoda, Kei Fukada
-
Publication number: 20140377347Abstract: The present invention relates to an in-situ multilayered tablet comprising at least one polymer layers and at least one drug layers wherein the said layers are physically separated from each other. After coming in contact with biological and/or aqueous fluids at least one of the polymer layers rapidly swells and sticks to one or more drug layers to form an in-situ multilayered tablet. Further, the polymer layer may optionally comprise a drug. Furthermore, the present invention relates to the processes for preparing said in-situ multilayered tablets.Type: ApplicationFiled: January 23, 2013Publication date: December 25, 2014Applicant: RANBAXY LABORATORIES LIMITEDInventors: Kumaravel Vivek, Anuj Kumar Fanda, Murali Krishna, Ravish Kumar Sharma, Kanwarpreet Singh Bakshi, Romi Barat Singh, Ajay Kumar Singla
-
Publication number: 20140378440Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Inventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, EMMANUEL VIAL, MICKAEL GUEDJ
-
Publication number: 20140371277Abstract: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.Type: ApplicationFiled: August 29, 2014Publication date: December 18, 2014Inventors: DANIEL COHEN, SERGUEI NABIROCHKIN, ILYA CHUMAKOV, RODOLPHE HAJJ
-
Publication number: 20140371229Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.Type: ApplicationFiled: August 29, 2014Publication date: December 18, 2014Inventors: DANIEL COHEN, SERGUEI NABIROCHKIN, ILYA CHUMAKOV, RODOLPHE HAJJ
-
Publication number: 20140371317Abstract: The present disclosure relates to compositions comprising: i) an aqueous silicone emulsion comprising; A) 0.5 wt % to 95 wt % of a silicone gum, resin, or PSA, B) 0.1 to 90 wt % of an ethylene oxide/propylene oxide block copolymer, and sufficient amount of water to sum all ingredients of the silicone gum emulsion to 100 weight percent, ii) a healthcare active, and iii) an optional enhancer(s).Type: ApplicationFiled: February 6, 2013Publication date: December 18, 2014Applicant: Dow Corning CorporationInventors: Hyder Aliyar, Robert O. Huber, Donald Taylor Liles, Gary L. Loubert, Gerald K. Schalau, II, SIMON Toth
-
Publication number: 20140371316Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropiomc acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).Type: ApplicationFiled: November 23, 2012Publication date: December 18, 2014Inventors: Jill S. FABRICANT, Iraj LALEZARI
-
Publication number: 20140364401Abstract: The present invention is directed to pharmaceutical compositions comprising antispasmodic C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid. Administration of the C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols with vitamin D3 is indicated for conditions such as bone loss, weight gain and autoimmune diseases such as lupus and rheumatoid arthritis.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Inventors: Priti Sanghvi Shah, Mandar V. Shah
-
Publication number: 20140364503Abstract: A ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition for the treatment of cardiac conditions and diagnosis applications, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (Esmolol hydrochloride), a buffering agent, ethanol and propylene glycol which capable of been stored in modified flexible plastic container, heat-sterilized without deformation and/or integrity of the closure system been compromised, as well as method for its manufacture, is disclosed.Type: ApplicationFiled: August 25, 2014Publication date: December 11, 2014Applicants: Welgrace Research Group, HQ SPECIALTY PHARMA CORPORATIONInventors: George OWOO, Erica CASTAGNA
-
Publication number: 20140363498Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Inventors: Amarpreet S. Sawhney, William H. Ransone, II
-
Publication number: 20140356290Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.Type: ApplicationFiled: June 6, 2014Publication date: December 4, 2014Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
-
Publication number: 20140356455Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.Type: ApplicationFiled: December 6, 2013Publication date: December 4, 2014Applicants: The Board of Trustees of the Leland Stanford Junior University, Parkinson's InstituteInventors: Renee Ann Reijo Pera, J. William Langston, Birgitt Schule, Theodore D. Palmer, Blake Byers, Ha Nam Nguyen, James Anthony Byrne, Branden John Cord
-
Publication number: 20140356439Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventors: Rimona MARGALIT, Dan PEER
-
Publication number: 20140357611Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventors: Krzysztof Palczewski, Akiko Maeda, Marcin Golczak
-
Publication number: 20140350019Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.Type: ApplicationFiled: September 7, 2012Publication date: November 27, 2014Applicant: FOVEA PHARMACEUTICALSInventors: John Feutrill, Caroline Leriche, David Middlemiss
-
Publication number: 20140349969Abstract: The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.Type: ApplicationFiled: May 8, 2014Publication date: November 27, 2014Inventors: Josef PENNINGER, Graham Gregory NEELY, Shane MCMANUS, Henrik NILSSON
-
Publication number: 20140350045Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).Type: ApplicationFiled: July 11, 2013Publication date: November 27, 2014Inventors: IRAJ LALEZARI, JILL FABRICANT
-
Publication number: 20140343152Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20140343153Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20140343000Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.Type: ApplicationFiled: July 24, 2014Publication date: November 20, 2014Inventors: Alicia Regueiro-Ren, Zheng Liu, Jacob Swidorski, Ny Sin, Brian Lee Venables, Sing-Yuen Sit, Yan Chen, Jie Chen, Nicholas A. Meanwell
-
Publication number: 20140336216Abstract: Provided herein are compounds capable of activating GPR139. Also provided are methods of increasing and decreasing the activity of GPR139. Methods of using the identified compounds to modulate GPR139 activity or conditions that may be affected by GPR139 activity are also disclosed.Type: ApplicationFiled: March 14, 2014Publication date: November 13, 2014Applicant: Janssen Pharmaceutica NVInventors: Curt A. Dvorak, Changlu Liu, Chester Kuei
-
Publication number: 20140328823Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20140328917Abstract: An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble.Type: ApplicationFiled: May 11, 2013Publication date: November 6, 2014Inventors: Takahiro Tada, Kazuhiro Kagami, Shiro Yokota
-
Publication number: 20140328778Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20140329835Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: June 19, 2014Publication date: November 6, 2014Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Publication number: 20140323575Abstract: The present invention relates to prevention or treatment of diseases related to abnormal cell proliferation, such as cancer, by administering meta- or ortho-tyrosine to a subject in need thereof, for instance a human subject. More specifically, the present invention provides isomers of tyrosine for its use in the prevention or treatment of a disease and in the preparation of pharmaceutical compositions, methods of treating or preventing diseases, such as cancer and cancer metastases, and pharmaceutical compositions containing meta- and/or ortho-tyrosine.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Inventors: Raul A. Ruggiero, Juan Bruzzo Iraola, Oscar Bustuoabad, Paula Chiarella, Roberto Meiss
-
Publication number: 20140322300Abstract: A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer contains diclofenac or a pharmaceutically acceptable salt thereof, glycerin, butylene glycol, and poly(ethylene glycol)monooleate, and a mass ratio between the butylene glycol and the poly(ethylene glycol)monooleate (mass of butylene glycol:mass of poly(ethylene glycol)monooleate) is 1:1 to 4:1.Type: ApplicationFiled: December 6, 2012Publication date: October 30, 2014Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Masaru Kijima, Yasuhisa Kose, Takaaki Yoshinaga
-
Publication number: 20140322304Abstract: Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.Type: ApplicationFiled: July 10, 2014Publication date: October 30, 2014Inventors: Gavin P. Robertson, Raghavendra Gowda Chandagalu D., Subbarao V. Madhunapantula, Gajanan S. Inamdar, Omer F. Kuzu
-
Publication number: 20140322164Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).Type: ApplicationFiled: May 31, 2012Publication date: October 30, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Gary L. Bloomgren, Carmen Bozic, Sophia Lee, Meena Subramanyam, Tatiana Plavina
-
Patent number: 8871809Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.Type: GrantFiled: September 12, 2013Date of Patent: October 28, 2014Assignee: Nuvo Research Inc.Inventors: Ed Kisak, Jagat Singh
-
Publication number: 20140314815Abstract: The present invention is drawn to adhesive solid gel-forming formulations, methods of drug delivery, and solidified gel layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a gelling agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified gel layer after at least a portion of the volatile solvent system is evaporated. The solidified gel layer is can be removed by peeling or washing.Type: ApplicationFiled: January 22, 2014Publication date: October 23, 2014Applicant: Nuvo Research Inc.Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20140314827Abstract: Described herein are compositions comprising at least one buffering agent, at least one chelating agent and at least one antimicrobial agent, which can be used for treating and/or preventing diseases or disorders in a variety of animals. In certain embodiments, in particular, the compositions can be used for treating and/or preventing ophthalmic and oral cavity diseases or disorders in dogs and cats and oropharyngeal and/or guttural pouch diseases or disorders in equines. In certain embodiments, the compositions can also be used for treating ophthalmic or oral cavity diseases or disorders in humans.Type: ApplicationFiled: April 17, 2014Publication date: October 23, 2014Inventor: Steven A. Melman
-
Publication number: 20140316007Abstract: The present invention relates to the combination of memantine and baclofen active ingredients, and also to the method for achieving body weight loss and thereby treating obesity and related co-morbidities by co-administration of baclofen and memantine.Type: ApplicationFiled: November 6, 2012Publication date: October 23, 2014Applicant: RICHTER GEDEON NYRT.Inventors: Péter Kovács, Tamás Kitka, Melinda Misnyovszki, Balázs Varga, Sándor Farkas, Csilla Mária Horváth
-
Publication number: 20140314842Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Patent number: 8865769Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.Type: GrantFiled: December 3, 2012Date of Patent: October 21, 2014Assignee: PharnextInventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
-
Publication number: 20140308241Abstract: Described are biomarkers including TOX useful for the diagnosis or prognosis of T cell malignancy. A level of a biomarker is determined in a sample from a subject and compared to a control level, wherein an increased level of the biomarker in the sample relative to the control level indicates that the subject has T cell malignancy. The T cell malignancy may be a cutaneous T cell lymphoma (CTCL) such as mycosis fungoides or Sezary syndrome.Type: ApplicationFiled: November 16, 2012Publication date: October 16, 2014Inventors: Youwen Zhou, Yuanshen Huang, Yang Wang, Ming-wan Su
-
Publication number: 20140308265Abstract: The claimed invention is directed to compositions and methods effective in preventing microbial contamination or reducing microbial count associated with a contaminated surface, comprising a biocidal system comprised of a primary biocide, a pH buffer agent, a surfactant, all in an aqueous based carrier, wherein the compositions may be considered environmentally friendly.Type: ApplicationFiled: November 6, 2012Publication date: October 16, 2014Inventors: Burt R. Sookram, John W. Veenstra
-
Publication number: 20140309190Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: June 17, 2014Publication date: October 16, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Ma Bin, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
-
Patent number: 8859539Abstract: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and ?v?3 integrin antagonist in the same molecule.Type: GrantFiled: November 1, 2010Date of Patent: October 14, 2014Assignee: Vascular Vision Pharmaceutical CompanyInventor: Shaker A. Mousa
-
Publication number: 20140302141Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: February 24, 2014Publication date: October 9, 2014Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: FERNANDO G. TONEGUZZO, GLENN A. MEYER, Marcelo A. RICCI, Marcelo A. COPPARI, ANA C. PASTINI, GUSTAVO A. FISCHBEIN
-
Publication number: 20140302134Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.Type: ApplicationFiled: September 7, 2012Publication date: October 9, 2014Inventor: Roland Saur-Brosch
-
Patent number: 8853189Abstract: The present invention is directed to pharmaceutical compositions comprising antispasmodic C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid. Administration of the C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols with vitamin D3 is indicated for conditions such as bone loss, weight gain and autoimmune diseases such as lupus and rheumatoid arthritis.Type: GrantFiled: March 13, 2013Date of Patent: October 7, 2014Assignee: Prima Innovations, LLCInventors: Priti Sanghvi Shah, Mandar V. Shah
-
Publication number: 20140296188Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.Type: ApplicationFiled: October 23, 2012Publication date: October 2, 2014Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
-
Patent number: 8846606Abstract: Provided herein are methods and compositions for treating septic hypotension. More specifically, the methods may comprise, administering one alpha-2 agonist or other sympatholytic and at least one vasopressor.Type: GrantFiled: June 24, 2011Date of Patent: September 30, 2014Inventor: Luc Quintin
-
Publication number: 20140288117Abstract: The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventor: Bill Piu CHAN
-
Publication number: 20140288034Abstract: A compound having an ability to bind to an S1P receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.Type: ApplicationFiled: June 4, 2014Publication date: September 25, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shinji NAKADE, Hirotaka Mizuno, Takeji ONO, Masashi Minami, Hiroshi Saga, Hiroshi Hagiya, Takaki Komiya, Hiromu Habashita, Haruto Kurata, Kazuhiro Ohtsuki, Kensuke Kusumi
-
Publication number: 20140288178Abstract: The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and/or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to inhibit c-Myc ubiquitination in cancerous cell populations, such as leukemic initiating cell populations, that are responsible for disease initiation and progression.Type: ApplicationFiled: October 29, 2012Publication date: September 25, 2014Applicant: NEW YORK UNIVERSITYInventors: Iannis Aifantis, Linsey Reavie, Shannon Buckley
-
Publication number: 20140286876Abstract: The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent.Type: ApplicationFiled: March 28, 2014Publication date: September 25, 2014Inventor: Andrew L. Skigen
-
MESALAMINE PHARMACEUTICAL COMPOSITION WITH MULTIPLE DOSAGE ELEMENTS FOR REDUCED DELIVERY VARIABILITY
Publication number: 20140271859Abstract: A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes mesalamine and an enteric coating. The enteric coating of each different dosage element differs so the release point of the mesalamine in the GI tract is varied. In one embodiment, a first dosage element releases about 30% to about 60% by weight of the total mesalamine in the composition after 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm and a second dosage element releases about 40% to about 70% by weight of the total mesalamine after 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Ryan Gerald LOUGHLIN, Stephen MCCULLAGH, Roger BOISSONNEAULT -
Publication number: 20140275261Abstract: The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyperlipidemia, and (8) is neither hypoallergenic nor vein irritating.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: DR. REDDY'S LABORATORIES, INC.Inventors: Franklin Okumu, Andrew Xian Chen, Hailiang Chen